Research programme: beta secretase inhibitors - Actelion
Alternative Names: Research programme: beta-secretase inhibitorLatest Information Update: 04 Nov 2017
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Amyloid beta-protein precursor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 27 Feb 2004 This programme is still in active development - (JP Morgan 22nd Annual Healthcare Conference)